Our Services
Medical Information
Helpful Resources
Published on: 8/18/2026
Bone density is reported as a T-score, with -1.0 and above considered normal, -1.1 to -2.4 indicating low bone mass (osteopenia), and -2.5 or lower meeting the definition of osteoporosis. Doctors typically start medication at a T-score of -2.5 or below, after a hip or spine fracture, or when osteopenia is paired with a 10-year fracture risk above roughly 3 percent for hip or 20 percent for major fractures on the FRAX tool. Age, prior fractures, steroid use, family history, and conditions like rheumatoid arthritis can shift that threshold, so two people with identical scores may receive very different advice, and there are several important factors to weigh before deciding. See below to understand how these numbers and risk factors work together. If you are dealing with back pain, height loss, unexplained fractures, or uncertainty about your results, a free, instant, online symptom check can help you organize your symptoms and understand which next steps and questions to bring to your doctor.
Last reviewed for medical accuracy: 08/18/2026
Bone density tests help doctors gauge how strong your bones are and whether you’re at risk for fractures. Learning what your results mean—and how they differ between osteopenia and osteoporosis—can guide timely treatment. Below, we explain bone density scores in clear terms, outline the differences between osteopenia vs. osteoporosis bone density, and show how doctors decide when to begin treatment.
Bone density, or bone mineral density (BMD), measures how much mineral (mostly calcium) you have in a section of bone. Higher BMD usually means stronger bones; lower BMD raises fracture risk.
• Dual-energy X-ray absorptiometry (DXA or DEXA): The standard scan for hip and spine.
• T-score: Compares your BMD to that of a healthy 30-year-old adult of the same sex.
• Z-score: Compares your BMD to what’s normal for your age, sex, and body size.
T-scores are used to classify bone health:
Doctors combine T-scores with other factors to decide on treatment.
Understanding the gap between osteopenia vs. osteoporosis bone density can ease your mind and guide your next steps.
Osteopenia
Osteoporosis
Both conditions signal that your bones aren’t as dense as they should be. Early intervention can slow or halt bone loss and lower fracture risk.
Doctors don’t rely on T-score alone. They consider a range of factors to determine if and when you need treatment:
Bone Density Score (T-score)
Fracture History
FRAX® Score
Age and Sex
Secondary Causes
Lifestyle Factors
Overall Health and Comorbidities
By weighing all these elements, your doctor creates a personalized plan that balances benefits and risks of treatment.
Whether you have osteopenia or osteoporosis, taking early action can protect your bones. Common approaches include:
When lifestyle changes alone aren’t enough, doctors may prescribe:
Your doctor will discuss the pros and cons, monitor side effects, and adjust as needed.
After starting treatment, regular follow-up is important:
Early detection of changes—good or bad—helps refine your plan.
If you’re experiencing bone pain, height loss, or new fractures, prompt evaluation is essential. You might also wonder whether other symptoms relate to bone health. For a free, online symptom check, consider using the doctor approved Ubie Symptom Checker.
Understanding the difference between osteopenia vs. osteoporosis bone density is your first step toward stronger bones. Here’s what you can do now:
Always speak to a doctor about anything that could be life-threatening or serious. Early action can make a lasting difference in your bone health and quality of life.
(References)
* Tuck SP, Francis RM. Osteoporosis. Postgrad Med J. 2002 Sep;78(923):526-32. doi: 10.1136/pmj.78.923.526. PMID: 12357012; PMCID: PMC1742482.
* Craig WJ. Health effects of vegan diets. Am J Clin Nutr. 2009 May;89(5):1627S-1633S. doi: 10.3945/ajcn.2009.26736N. Epub 2009 Mar 11. PMID: 19279075.
* De Souza MJ, Nattiv A, Joy E, Misra M, Williams NI, Mallinson RJ, Gibbs JC, Olmsted M, Goolsby M, Matheson G, Expert Panel. 2014 Female Athlete Triad Coalition Consensus Statement on Treatment and Return to Play of the Female Athlete Triad: 1st International Conference held in San Francisco, California, May 2012 and 2nd International Conference held in Indianapolis, Indiana, May 2013. Br J Sports Med. 2014 Feb;48(4):289. doi: 10.1136/bjsports-2013-093218. PMID: 24463911.
* Beck BR, Daly RM, Singh MA, Taaffe DR. Exercise and Sports Science Australia (ESSA) position statement on exercise prescription for the prevention and management of osteoporosis. J Sci Med Sport. 2017 May;20(5):438-445. doi: 10.1016/j.jsams.2016.10.001. Epub 2016 Oct 31. PMID: 27840033.
* Yedavally-Yellayi S, Ho AM, Patalinghug EM. Update on Osteoporosis. Prim Care. 2019 Mar;46(1):175-190. doi: 10.1016/j.pop.2018.10.014. Epub 2018 Dec 24. PMID: 30704657.
* Anderson PA, Binkley NC, Bernatz JT. Bone Health Optimization (BHO) in Spine Surgery. Spine (Phila Pa 1976). 2023 Jun 1;48(11):782-790. doi: 10.1097/BRS.0000000000004618. Epub 2023 Mar 13. PMID: 36917718.
* Shevroja E, Reginster JY, Lamy O, Al-Daghri N, Chandran M, Demoux-Baiada AL, Kohlmeier L, Lecart MP, Messina D, Camargos BM, Payer J, Tuzun S, Veronese N, Cooper C, McCloskey EV, Harvey NC. Update on the clinical use of trabecular bone score (TBS) in the management of osteoporosis: results of an expert group meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO), and the International Osteoporosis Foundation (IOF) under the auspices of WHO Collaborating Center for Epidemiology of Musculoskeletal Health and Aging. Osteoporos Int. 2023 Sep;34(9):1501-1529. doi: 10.1007/s00198-023-06817-4. Epub 2023 Jul 1. PMID: 37393412; PMCID: PMC10427549.
* Humphrey MB, Russell L, Danila MI, Fink HA, Guyatt G, Cannon M, Caplan L, Gore S, Grossman J, Hansen KE, Lane NE, Ma NS, Magrey M, McAlindon T, Robinson AB, Saha S, Womack C, Abdulhadi B, Charles JF, Cheah JTL, Chou S, Goyal I, Haseltine K, Jackson L, Mirza R, Moledina I, Punni E, Rinden T, Turgunbaev M, Wysham K, Turner AS, Uhl S. 2022 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. Arthritis Rheumatol. 2023 Dec;75(12):2088-2102. doi: 10.1002/art.42646. Epub 2023 Oct 16. PMID: 37845798.
* Ha J, Lee YJ, Kim J, Jeong C, Lim Y, Lee J, Baek KH, Catholic Medical Center Bone Research Group. Long-Term Efficacy and Safety of Denosumab: Insights beyond 10 Years of Use. Endocrinol Metab (Seoul). 2025 Feb;40(1):47-56. doi: 10.3803/EnM.2024.2125. Epub 2025 Jan 13. PMID: 39801038; PMCID: PMC11898325.
* Kobayakawa T. Sequential and combination therapy with romosozumab. J Bone Miner Metab. 2025 Jan;43(1):10-17. doi: 10.1007/s00774-025-01590-2. Epub 2025 Mar 1. PMID: 40024934.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.